基石药业-B现涨逾4% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据

新浪港股
16 Dec 2024
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  基石药业-B(02616)早盘上涨3.80%,现报2.73港元,成交额1450.93万港元。

  近日,基石药业-B公布,将在第66届美国血液学会(ASH)年会上,公布管线2.0重磅产品CS5001(ROR1 ADC)针对淋巴瘤的最新临床数据。公告指出,CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10